Osteonecrosis of the Jaw (ONJ) Case Registry

Status Completed

Clinical Trial Summary

Clinical Trial Description

The purpose of the ONJ case registry is to describe the natural history of positively-adjudicated ONJ in subjects with cancer with an observation period of 5 years. Most of these subjects are expected to have received bone antiresorptive agents such as bisphosphonates or denosumab together with cancer-specific therapies (eg, chemotherapy, steroids, or anti-angiogenics). It is also possible that the registry will include subjects with cancer who developed ONJ without exposure to any antiresorptive therapy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01666106
Study type	Observational
Source	Amgen
Contact
Status	Completed
Phase
Start date	October 1, 2012
Completion date	December 16, 2020

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06419010` - Leukocyte- and Platelet-Rich Fibrin in the Surgical Treatment of Medication-related Osteonecrosis of the Jaw	N/A
Enrolling by invitation	`NCT05329558` - Local and Systemic Changes in Osteonecrosis of the Jawbone
Completed	`NCT01201330` - DPBRN Retrospective Cohort Study of Osteonecrosis of the Jaw	N/A
Completed	`NCT01130389` - CONDOR Study of Osteonecrosis of the Jaws (TMJ)	N/A
Completed	`NCT01967160` - Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid
Recruiting	`NCT06457776` - Medication Related Osteonecrosis of the Jaws (MRONJ) in a Cohort of Patients Treated by Antiresorptive Drugs